Table 2.
Proportion of participants experiencing adverse events leading to treatment discontinuation according to study level characteristics.
| Comparison | Studies | % (95% CI) | I2 | p value |
|---|---|---|---|---|
| Overall | 27 | 6.6 (4.4–9.0) | 48.7 | NA |
| Rush Phase | ||||
| Yes | 17 | 7.3 (4.7–10.3) | 47.2 | 0.532 |
| No | 10 | 5.3 (1.8–10.1) | 50.1 | |
| Co-Treatment | ||||
| No | 20 | 8.5 (6.5–10.8) | 17.7 | 0.003 |
| Yes | 8 | 1.4 (0–5.2) | 39.5 | |
| Antihistamine Alone | 3 | 10.3 (4.1–23.6) | NA | |
| Antihistamine + Montelukast | 1 | 0.0 (0.0–14.9) | NA | |
| Omalizumab | 2 | 7.2 (0.5–14.9) | NA | |
| Probiotic | 3 | 0.0 (0.0–3.9) | NA | |
| Maintenance Dose (mg/day) | ||||
| <1000 | 14 | 5.6 (2.8–9.1) | 53.8 | 0.328 |
| ≥1000 | 12 | 7.7 (4.1–12.1) | 50.4 | |
| Entry OFC | ||||
| DBPCFC | 13 | 9.2 (6.8–12.0) | 7.8 | 0.086 |
| Open | 7 | 3.8 (0.7–8.4) | 31.9 | |
| None | 7 | 4.8 (0.9–10.8) | 71.6 | |
| Baseline psIgE (kU/L) | ||||
| <60 | 10 | 2.2 (0.2–5.7) | 41.0 | <0.001 |
| ≥60 | 14 | 10.0 (7.8–12.5) | 0.00 | |
| Baseline SPT (mm) | ||||
| <12 | 11 | 7.7 (5.1–10.7) | 36.9 | 0.422 |
| ≥12 | 9 | 4.0 (0.3–10.0) | 46.3 | |
Abbreviations: psIgE, peanut specific IgE; SPT, skin prick test; NA, not applicable.